References
- Jacobson PA, Ng J, Green KGE, et al. Post transplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003;9(5):304–311.
- Parquet N, Reigneau O, Humbert H, et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2000;25(9):965–968.
- Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion based formulation (Neoral)1 in organ transplantation. Drugs. 2001;61(13):1957–2016.
- Schiller D, Fung H. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007;29(9):1862–1886.
- Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21(5):645–653.
- Sanchez-Ortega I, Vazquez L, Montes C, et al. Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrob Agents Chemother. 2012;56(12):6422–6424.
- Atiq F, Hameli E, Broers AEC, et al. Converting cyclosporine a from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals. Eur J Clin Pharmacol. 2018;74(6):767–773.
- Carreras E, Dufour C, Mohty M, et al., editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham, Switzerland: Springer; 2019.
- Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729–735.
- Robinson D, Hughes C, Grigg A. Optimal oral cyclosporine dosing with concomitant posaconazole post allogeneic stem cell transplantation. Leuk Lymphoma. 2020;61(10):2448–2452.
- Hoyt R, Ritchie D, Roberts A, et al. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant. 2008;41(7):651–658.
- Chau MM, Daveson K, Alffenaar JC, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J. 2021;51(Suppl. 7):37–66.
- Marciano KA, Seago K, Dillaman M, et al. Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients. Transplant Cell Ther. 2022;28(7):371.e1–371.e4.